# Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

> **NCT06738745** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 90 (estimated)

## Conditions studied

- Prostate Cancer Metastatic Disease

## Interventions

- **DRUG:** HRS-2189
- **DRUG:** HRS-5041

## Key facts

- **NCT ID:** NCT06738745
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-31
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06738745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06738745, "Study of HRS-2189 Combined HRS-5041 in Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06738745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*